Physician profile
Christopher Michael Ward
NPI 1659858256
$915.76
in general payments reported to CMS, 2019-2025
15 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $405 · 2024: $400 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $915.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $246.55 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $131.42 | 2023 | Sotyktu |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $118.58 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $90.14 | 2023-2024 | Rexulti, Abilify Maintena |
| Gilead Sciences, INC. | $64.14 | 2024 | |
| Indivior INC. | $62.90 | 2023-2024 | Sublocade |
| Supernus Pharmaceuticals, INC. | $45.92 | 2024 | Qelbree |
| Novo Nordisk INC | $33.58 | 2023-2024 | Ozempic, Rybelsus |
| Alkermes, INC. | $23.33 | 2025 | Vivitrol |
| Glaxosmithkline, LLC. | $17.65 | 2024 | Bexsero |
| Lilly USA, LLC | $17.04 | 2025 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $17.00 | 2023 | |
| Braeburn INC. | $16.11 | 2024 | Brixadi |
| Astrazeneca Pharmaceuticals LP | $15.92 | 2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.48 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.